▲ 0.35%
prev close
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-01-31 | ARWRArrowhead Pharmaceuticals, Inc. | Sell | $1,001 - $15,000 | 1133d ago | — |
2023-01-31
Daniel Goldman
ARWR
Amount
$1,001 - $15,000
Filed
1133d ago
Recent News
Powered by Polygon.io
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-01-31 · Sale
$1,001 - $15,000